Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio, Rome, Italy.
Curr Opin Allergy Clin Immunol. 2021 Oct 1;21(5):455-464. doi: 10.1097/ACI.0000000000000779.
To provide the most recent insights in the use of biologicals in the treatment of patients with anaphylaxis.
There is evidence that biologics such as omalizumab may be safe and effective in preventing anaphylactic reactions in patients at high risk mainly because of severe food allergy or desensitization procedures to food, airborne allergen, drugs, or hymenoptera venom.
Further knowledge will guide the adoption and implementation of any new therapy including biologics for anaphylaxis according to the stratification of risk/benefits.
提供生物制剂治疗过敏反应患者的最新见解。
有证据表明，奥马珠单抗等生物制剂可能对高风险患者预防过敏反应安全且有效，主要是因为严重食物过敏或食物、空气过敏原、药物或蜂毒液脱敏治疗。
进一步的知识将指导根据风险/获益分层，对过敏反应采用和实施任何新的治疗方法，包括生物制剂。
